1. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
- Author
-
Momeny, Majid, Esmaeili, Fatemeh, Hamzehlou, Sepideh, Yousefi, Hassan, Javadikooshesh, Sepehr, Vahdatirad, Vasimeh, Alishahi, Zivar, Mousavipak, Seyedeh H., Bashash, Davood, Dehpour, Ahmad R., Tavangar, Seyyed M., Tavakkoly-Bazzaz, Javad, Haddad, Peiman, Kordbacheh, Farzaneh, Alimoghaddam, Kamran, Ghavamzadeh, Ardeshir, and Ghaffari, Seyed H.
- Subjects
SURVIVIN (Protein) ,WESTERN immunoblotting ,CELL migration ,THERAPEUTICS ,METASTASIS ,CELL migration inhibition - Abstract
Purpose: Pancreatic ductal adenocarcinoma (PDAC), the most common malignancy of the pancreas, is the fourth most common cause of cancer-related death in the USA. Local progression, early tumor dissemination and low efficacy of current treatments are the major reasons for its high mortality rate. The ERBB family is over-expressed in PDAC and plays essential roles in its tumorigenesis; however, single-targeted ERBB inhibitors have shown limited activity in this disease. Here, we examined the anti-tumor activity of dacomitinib, a pan-ERBB receptor inhibitor, on PDAC cells. Methods: Anti-proliferative effects of dacomitinib were determined using a cell proliferation assay and crystal violet staining. Annexin V/PI staining, radiation therapy and cell migration and invasion assays were carried out to examine the effects of dacomitinib on apoptosis, radio-sensitivity and cell motility, respectively. Quantitative reverse transcription-PCR (qRT-PCR) and Western blot analyses were applied to elucidate the molecular mechanisms underlying the anti-tumor activity of dacomitinib. Results: We found that dacomitinib diminished PDAC cell proliferation via inhibition of FOXM1 and its targets Aurora kinase B and cyclin B1. Moreover, we found that dacomitinib induced apoptosis and potentiated radio-sensitivity via inhibition of the anti-apoptotic proteins survivin and MCL1. Treatment with dacomitinib attenuated cell migration and invasion through inhibition of the epithelial-to-mesenchymal transition (EMT) markers ZEB1, Snail and N-cadherin. In contrast, we found that the anti-tumor activity of single-targeted ERBB agents including cetuximab (anti-EGFR mAb), trastuzumab (anti-HER2 mAb), H3.105.5 (anti-HER3 mAb) and erlotinib (EGFR small molecule inhibitor) were marginal. Conclusions: Our findings indicate that dacomitinib-mediated blockade of the ERBB receptors yields advantages over single-targeted ERBB inhibition and provide a rationale for further investigation of the therapeutic potential of dacomitinib in the treatment of ERBB-driven PDAC. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF